Market Cap 75.79M
Revenue (ttm) 71.23M
Net Income (ttm) -51.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -72.90%
Debt to Equity Ratio -1.90
Volume 500
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 688.95M
Stochastic %K N/A
Beta 12.76
Analysts Strong Buy
Price Target N/A

Company Profile

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Poliste...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 44 1903 844 700
Address:
Dominion Way, Worthing, United Kingdom
Latest News on AGYTF
No data available.